Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells - PubMed (original) (raw)
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells
Shingo Kozono et al. Cancer Res. 2013.
Abstract
Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells and confer resistance to established treatments. We investigated whether the antifibrotic agent pirfenidone can suppress desmoplasia and exert antitumor effects against pancreatic cancer. Primary PSCs were established from pancreatic cancer tissue obtained during surgery. In vitro, pirfenidone inhibited the proliferation, invasiveness, and migration of PSCs in a dose-dependent manner. Although supernatants of untreated PSCs increased the proliferation, invasiveness, and migration of pancreatic cancer cells (PCC), supernatants of pirfenidone-treated PSCs decreased these effects. Exposure to PCC supernatant increased the production of platelet-derived growth factor-A, hepatic growth factor, collagen type I, fibronectin, and periostin in PSCs, which was significantly reduced by pirfenidone. Mice were subcutaneously implanted with PCCs (SUIT-2 cells) and PSCs into the right flank and PCCs alone into the left flank. Oral administration of pirfenidone to these mice significantly reduced tumor growth of co-implanted PCCs and PSCs, but not of PCCs alone. Pirfenidone also decreased the proliferation of PSCs and the deposition of collagen type I and periostin in tumors. In mice with orthotopic tumors consisting of PCCs co-implanted with PSCs, pirfenidone suppressed tumor growth, reduced the number of peritoneal disseminated nodules, and reduced the incidence of liver metastasis. Pirfenidone in combination with gemcitabine more effectively suppressed orthotopic tumor growth compared with pirfenidone or gemcitabine alone. In conclusion, our findings indicate that pirfenidone is a promising antitumor agent for pancreatic cancer, owing to its suppression of desmoplasia through regulating PSCs.
©2013 AACR.
Similar articles
- Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L. Liu Y, et al. Tumour Biol. 2016 Nov;37(11):15283-15291. doi: 10.1007/s13277-016-5321-6. Epub 2016 Sep 30. Tumour Biol. 2016. PMID: 27696296 - Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model.
Yoshida M, Miyasaka Y, Ohuchida K, Okumura T, Zheng B, Torata N, Fujita H, Nabae T, Manabe T, Shimamoto M, Ohtsuka T, Mizumoto K, Nakamura M. Yoshida M, et al. Cancer Sci. 2016 Oct;107(10):1443-1452. doi: 10.1111/cas.13024. Epub 2016 Sep 24. Cancer Sci. 2016. PMID: 27487486 Free PMC article. - Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Duan W, Chen K, Jiang Z, Chen X, Sun L, Li J, Lei J, Xu Q, Ma J, Li X, Han L, Wang Z, Wu Z, Wang F, Wu E, Ma Q, Ma Z. Duan W, et al. Cancer Lett. 2017 Jan 28;385:225-233. doi: 10.1016/j.canlet.2016.10.019. Epub 2016 Oct 20. Cancer Lett. 2017. PMID: 27773749 - Key role of pancreatic stellate cells in pancreatic cancer.
Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Pothula SP, et al. Cancer Lett. 2016 Oct 10;381(1):194-200. doi: 10.1016/j.canlet.2015.10.035. Epub 2015 Nov 10. Cancer Lett. 2016. PMID: 26571462 Review. - [The impact of desmoplasia and pancreatic stellate cells on pancreatic cancer].
Nielsen MF, Mortensen MB, Detlefsen S. Nielsen MF, et al. Ugeskr Laeger. 2015 Aug 17;177(34):V01150079. Ugeskr Laeger. 2015. PMID: 26320589 Review. Danish.
Cited by
- Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.
Branco H, Oliveira J, Antunes C, Santos LL, Vasconcelos MH, Xavier CPR. Branco H, et al. Int J Mol Sci. 2022 Mar 26;23(7):3631. doi: 10.3390/ijms23073631. Int J Mol Sci. 2022. PMID: 35408988 Free PMC article. - Targeting transforming growth factor beta (TGF-β) using Pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer.
Jamialahmadi H, Nazari SE, TanzadehPanah H, Saburi E, Asgharzadeh F, Khojasteh-Leylakoohi F, Alaei M, Mirahmadi M, Babaei F, Asghari SZ, Mansouri S, Khalili-Tanha G, Maftooh M, Fiuji H, Hassanian SM, Ferns GA, Khazaei M, Avan A. Jamialahmadi H, et al. Sci Rep. 2023 Sep 1;13(1):14357. doi: 10.1038/s41598-023-41550-2. Sci Rep. 2023. PMID: 37658230 Free PMC article. - Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5.
Ando Y, Ohuchida K, Otsubo Y, Kibe S, Takesue S, Abe T, Iwamoto C, Shindo K, Moriyama T, Nakata K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. Ando Y, et al. PLoS One. 2020 Jan 30;15(1):e0228015. doi: 10.1371/journal.pone.0228015. eCollection 2020. PLoS One. 2020. PMID: 31999765 Free PMC article. - Repositioning of duloxetine to target pancreatic stellate cells.
Sagara A, Nakata K, Matsumoto S, Guan W, Shinkawa T, Iwamoto C, Ikenaga N, Ohuchida K, Nakamura M. Sagara A, et al. Oncol Lett. 2021 Oct;22(4):744. doi: 10.3892/ol.2021.13005. Epub 2021 Aug 20. Oncol Lett. 2021. PMID: 34466156 Free PMC article. - The pancreatic cancer microenvironment: A true double agent.
Melstrom LG, Salazar MD, Diamond DJ. Melstrom LG, et al. J Surg Oncol. 2017 Jul;116(1):7-15. doi: 10.1002/jso.24643. Epub 2017 Jun 12. J Surg Oncol. 2017. PMID: 28605029 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical